9D9抗体在CT26结肠癌模型中怎么给药？

Figure 4 CTLA-4 blockade is less effective in aged mice. CT26 tumor cells were subcutaneously implanted on the flank of female BALB/c mice either at 6-8 weeks old (young) or at 60-72 weeks old (aged). (A, B) The mice were treated with anti-CTLA-4 antibody IP at 10 mg/kg twice weekly starting 7 days after tumor cell implantation for a total of 6 doses. (A) Kaplan-Meier curves showing time-to-welfare endpoint. 38 mice per group. (B) Fold change in rate of tumor growth for each animal in both young and aged mice after anti-CTLA-4 antibody treatment compared to age-matched untreated mice. 38 mice per group. (C, D) The mice were treated IP at 10 mg/kg twice weekly for a total of 6 doses with a combination of anti-PD-L1 antibody (starting 4 days after tumor cell implantation) and anti-CTLA-4 antibody (starting 7 days after tumor cell implantation). (C) Kaplan-Meier curves showing time-to-welfare endpoint. 37-38 mice per group. (D) Fold change in rate of tumor growth for each animal in both young and aged mice after anti-PD-L1 and anti-CTLA-4 antibodies compared to age-matched untreated mice. 37-38 mice per group. The results in panels (A, B) include data from 3 experiments and the results in panels (C, D) include data from 4 experiments. ns, non-significant, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001.
1610月

9D9抗体在CT26结肠癌模型中怎么给药？

1、用量参考

抗小鼠CTLA-4单克隆抗体（克隆号：9D9）在小鼠肿瘤模型和其他小鼠模型中通常用于体内CTLA-4中和、肿瘤内调节性T细胞耗竭等研究。9D9抗体在设计使用进行体内研究时，确定其给药的最优剂量和方案是非常重要。根据现有文献报道，我们简要总结了抗小鼠CTLA-4单抗（9D9）在CT26结肠癌模型 (CT26 colon carcinoma model) 中的给药方案，仅供参考。详情如下表（注意：手机左右滑动查看完整表格）：

参数 描述
动物模型 CT26结肠癌模型
实验动物 BALB/c 雌性小鼠（6-8周龄，体重18-22g）
给药途径 腹腔注射 (i.p.)
单只剂量 100-200 μg/次（约5-10 mg/kg，根据体重调整）
给药间隔 每3天一次
总给药次数 3-4次
动物数 5-10 只/组（实验组、对照组）
起始时间 肿瘤接种后7-10天（肿瘤体积50-100 mm³）
对照建议 相同亚型的同型对照IgG（如小鼠IgG2b）

* 以上为常见方案范围，最佳剂量与频次需结合动物状态与实验目的优化。

2、参考文献

1.Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer. Schofield DJ, et al. mAbs. 2021;13(1):1857100. doi: 10.1080/19420862.2020.1857100. PMID: 33397194

2.Preclinical dose-pharmacokinetic-efficacy modeling of botensilimab using a mouse surrogate of the Fc-enhanced anti-CTLA-4 antibody. Savitsky D, et al. J Immunother Cancer. 2024;12(Suppl 2):A598. doi: 10.1136/jitc-2024-SITC2024.0527.

3.Anti-CTLA4 activates intratumoral NK cells and combination with IL15/IL15Rα complexes enhances tumor control. Sanseviero E, et al. Cancer Immunol Res. 2019;7(8):1371-1380. doi: 10.1158/2326-6066.CIR-18-0386. PMID: 31239316

4.AGEN1181, an Fc-Enhanced Anti-CTLA-4 Antibodies Engage Multiple Mechanisms of Action to Promote T Cell-Mediated Anti-Tumor Immunity. Tanne A, et al. AACR. 2020.

5.Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy. Chand D, et al. Cancer Discov. 2024;14(12):2407.

由于篇幅限制，以上仅展示了抗小鼠CTLA-4单克隆抗体(9D9)用于CT26结肠癌模型的部分参考文献。如果您想要了解更多文献，欢迎联系我们（咨询微信：duozhaozhao2024）。

3、推荐产品

您是否在寻求价格合理、高质量的9D9抗体来推进您的研究？Syd Labs以提供体内实验级重组抗小鼠CTLA-4单克隆抗体（克隆号9D9）而闻名，如低内毒素（内毒素1 EU/mg）、极低内毒素（内毒素可低至0.05 EU/mg）、运用重组技术实现了不同分型的自由切换（小鼠版本、Fc沉默版本）。

查找Syd Labs 抗小鼠CTLA-4重组抗体（9D9）产品：抗小鼠CTLA-4单克隆抗体 (9D9)多种型

4、抗小鼠CTLA-4单抗(9D9)在不同小鼠肿瘤模型中的给药方案：

抗小鼠CTLA-4单抗(9D9)在B16黑色素瘤模型中怎么给药？
抗小鼠CTLA-4抗体(9D9)在MC38结肠腺癌模型中怎么给药？
9D9抗体在CT26结肠癌模型中怎么给药？
抗小鼠CTLA-4单抗(9D9)在Sa1N纤维肉瘤模型中怎么给药？
抗小鼠CTLA-4抗体(9D9)在EMT6乳腺癌模型中怎么给药？
9D9抗体在SW1黑色素瘤模型中怎么给药？
抗小鼠CTLA-4单抗(9D9)在TC1肺癌模型中怎么给药？
抗小鼠CTLA-4抗体(9D9)在ID8卵巢癌模型中怎么给药？
9D9抗体在胃肠道间质瘤模型中怎么给药？
抗小鼠CTLA-4单抗(9D9)在4T1乳腺癌模型中怎么给药？
抗小鼠CTLA-4抗体(9D9)在Hepa1-6肝细胞癌模型中怎么给药？
9D9抗体在不同小鼠肿瘤模型中怎么给药？

产品新闻, 新闻, 资讯 , , , , , , ,